leisure time -WSS

leisure time

author：comprehensive 2025-09-29 21:25:56 - browse：5

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： How to increase colonoscopy rates? Looks like an AI can help

WSS

Why a market frenzy over new weight loss drugs defies logic

FDA's Pazdur wants cancer trials to range beyond China alone

Change Healthcare can notify patients about the breach, HHS says

UnitedHealth, Optum discontinue NaviHealth name

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Health tech investors get more selective as pandemic boom fades

leisure time

leisure time

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA clears Verve to begin U.S. study of gene

Medical records are filled with copy

Study on Amgen’s bispecific immunotherapy produces positive data

Novavax promises a turnaround & Lilly roils the obesity market

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

In Memoriam: Notable people who died in 2023

J&J lung cancer data amount to new salvo against AstraZeneca

Malaria cases in Florida and Texas: Here’s what you need to know

Why a market frenzy over new weight loss drugs defies logic

entertainment

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

ADCs take center stage as promising cancer treatments

STAT Summit: Meghan O’Rourke on making chronic illness visible

Readout LOUD podcast: Live from the 2023 STAT Summit

Smaller biotechs seek to piggyback on weight loss drug boom

Ionis drug prevents swelling attacks due to hereditary angioedema

hotspot

explore

Wikipedia

entertainment